Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Provence Technologies Launches New USD 1.7 Million Research Programme

Published: Tuesday, January 29, 2013
Last Updated: Monday, January 28, 2013
Bookmark and Share
Screening 1000, the research project conducted by Provence Technologies, is set up to find and market a new ultra-pure molecule.

Provence Technologies has announced the launch of Screening 1000, a new USD 1.7 million (EUR 1.3 million) research programme with the goal of discovering a new ultra-pure molecule for the healthcare market.

The project is being launched by the R&D department of Provence Technologies and is being co-financed equally by Oseo, the French innovation promotion agency and Provence Technologies.

The programme is planned to run for two years and aims to develop a new range of products.

Screening 1000 will firstly analyze 1000 chemical compounds already on the market and detect those that show anomalies in purity. The use of already known compounds allows an existing range to be optimized, thereby reducing development costs.

Provence Technologies will then focus on new compounds with the most promising market potential. To help achieve this, the company will develop new approaches to purification and synthesis, making it possible to meet the purity levels required by health regulations.

“We hope this research project will create as much success as Provence Technologies enjoyed with our efforts around methylene blue. The really innovative part of this program is implementing new solutions in the fields of purification of active principles or alternative synthesis pathways,” said Claude Monteils, internal R&D project coordinator, Provence Technologies.

Monteils continued, “We are delighted that the French innovation promotion agency Oseo, which is a traditional partner of Provence Technologies, is joining us in this highly promising project and again supporting us in our strategy of innovation.”

“As well as providing R&D services in the field of fine chemistry, Provence Technologies will continue to develop its own internal research projects and proprietary research efforts,” said Dr Babak Sayah, chief operating officer, Provence Technologies.

Dr Sayah continued, “This new programme demonstrates the high added value of our own technologies in finding new uses for molecules, both old and new, in response to increasingly high stakes in public health.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More Than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Provence Technologies Acquires Synprosis
The acquisition strengthens Provence Technologies’ expertise in its core business of therapeutic chemistry.
Tuesday, June 03, 2014
Provence Technologies and Provepharm Invest EUR 4 Million in their New Head Office
The group will also use the investment to set up an incubator for health care industry start-ups.
Thursday, January 30, 2014
Provence Technologies Increases its Capital to EUR One Million
Underpinned by a stronger financial structure, the company will develop new projects for rehabilitating compounds of proven therapeutic potential.
Thursday, September 06, 2012
Provence and Neuroptis Biotech Partner to Develop a New Compound for Treating Dry Eye Syndrome
Provence Technologies to optimize and transfer the production process for ML7, Neuroptis Biotech’s dry eye drug candidate.
Wednesday, May 23, 2012
Provence Technologies and NexGenix Announce Successful Lead Compound Development
Both companies have been collaborating on the synthesis optimization and pre industrialization of innovative molecule targeting Hsp90.
Wednesday, July 06, 2011
Scientific News
Ketamine Metabolism Lifts Depression
NIH-funded team finds rapid-acting, non-addicting agent in mouse study.
Faster, Cheaper Way to Produce New Antibiotics
A novel way of synthesising a promising new antibiotic has been identified by scientists at the University of Bristol.
Process Contaminants in Vegetable Oils and Foods
Glycerol-based process contaminants found in palm oil, but also in other vegetable oils, margarines and some processed foods, raise potential health concerns for average consumers of these foods in all young age groups, and for high consumers in all age groups.
Improving Natural Killer Cancer Therapy
Vanderbilt University researchers discover transcription factor critical for NK cell expansion. Findings could lead to increased therapeutic efficacy.
Molecular Mechanism For Generating Specific Antibody Responses Discovered
Study could spur more ways to treat autoimmune disease, develop accurate vaccines.
Monovar Drills Down Into Cancer Genome
Rice, MD Anderson develop program to ID mutations in single cancer cells.
It’s Now Easier To Go With The Flow
Rice University tool simplifies comparison of flow cytometry data for laboratories.
Autism, Cancer Share a Remarkable Number of Risk Genes
Researchers with the UC Davis Comprehensive Cancer Center, MIND Institute identify more than 40 common genes.
Number Of Known Genetic Risk Factors For Endometrial Cancer Doubled
An international collaboration of researchers has identified five new gene regions that increase a woman’s risk of developing endometrial cancer, one of the most common cancers to affect women, taking the number of known gene regions associated with the disease to nine.
Genetic Variant May Help Explain Why Labradors Are Prone To Obesity
A genetic variation associated with obesity and appetite in Labrador retrievers – the UK and US’s favourite dog breed – has been identified by scientists at the University of Cambridge. The finding may explain why Labrador retrievers are more likely to become obese than dogs of other breeds.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!